Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ifosfamide
Find trials that include:  Any drugs shown
Results 1-24 of 24 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Phase: Phase III
Type: Treatment
Age: 14 and over
Trial IDs: A031102, NCI-2014-01696, PA031102_A01PAMDREVW01, NCT02375204
Panobinostat and Combination Chemotherapy in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0065, NCI-2012-01779, NCI-2010-01770, NCT01169636
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 74
Trial IDs: I 240813, NCI-2013-01784, NCT01959698
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9111, NCI-2014-01782, NCT02227199
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 10 to 69
Trial IDs: MT2005-21, NCI-2010-01700, 2006LS032, UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094
High-Dose Chemotherapy, Bevacizumab and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936
Ofatumumab, Combination Chemotherapy, and Filgrastim Before Stem Cell Collection in Treating Patients with Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 2009-0796, NCI-2011-01068, NCT01329900
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CD-ON-MEDI-551-1088, NCI-2012-00735, NCT01453205
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Phase: Phase II
Type: Supportive care, Treatment
Age: 3 to 21
Trial IDs: ACNS1123, NCI-2012-01967, CDR0000734032, COG-ACNS1123, NCT01602666
Irinotecan Hydrochloride, Temozolomide, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Ewing Sarcoma
Phase: Phase II
Type: Treatment
Age: 1 to 40
Trial IDs: 13-068, NCI-2013-01094, NCT01864109
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ANHL12P1, NCI-2013-02167, COG-ANHL12P1, NCT01979536
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9464, NCI-2013-02414, NCT02050919
Combination Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage I-II Nasal NK Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0367, NCI-2014-01356, NCT02106988
Combination Chemotherapy with or without Ganitumab in Treating Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1221, NCI-2014-02380, NCT02306161
Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0183, NCI-2012-00847, NCT01590732
Fludarabine Phosphate, Cyclophosphamide, and Laboratory-Treated T Cells in Treating Younger Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 12-C-0112, NCI-2013-01518, 120112, P09594, NCT01593696
Ibrutinib and Combination Chemotherapy in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-145, NCI-2014-00571, 9588, NCT02219737
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients with Soft Tissue Sarcoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7487, NCI-2011-02488, NCT01446809
Start Over